Patents by Inventor Donald G. Wallace
Donald G. Wallace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11518968Abstract: A method for expediting the production of aged whiskey. The method uses a system including a tank with a lid containing charred wood slabs and a degasser connected via a conduit to a tube having a vacuum valve, a pressure release valve, and a vacuum gauge. Distillate is delivered to the tank and cyclical steps are applied to age the distillate while regulating the amount of vacuum developed in the tank. The degasser is energized and the vacuum valve is opened, subjecting the distillate to vacuum. The vacuum valve closed and the degasser is de-energized. The pressure in the system is held for approximately one minute. The pressure release valve is slowly opened, allowing the pressure to neutralize to atmospheric pressure. The pressure release valve is closed and the system sits for at least 1.5 hours. Finally, these cyclical steps are repeated for 21 days or more.Type: GrantFiled: August 16, 2019Date of Patent: December 6, 2022Assignee: LIBERTY REAL ESTATE HOLDINGS, LLCInventors: Donald E. Fitzpatrick, Patrick G. Wallace
-
Publication number: 20140120078Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: December 9, 2013Publication date: May 1, 2014Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
-
Publication number: 20140086898Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: August 19, 2013Publication date: March 27, 2014Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian
-
Patent number: 8617584Abstract: The present invention relates generally to synthetic polymer compositions that form interpenetrating polymer networks. In a preferred embodiment, the compositions comprise two multifunctionally activated synthetic polymers, along with a tensile strength enhancer. Such compositions form matrices that exhibit superior cohesive strength and in many instances can serve as adequate replacements for surgical means of attaching tissues, such as sutures, sponges and medical staples.Type: GrantFiled: May 25, 2010Date of Patent: December 31, 2013Assignee: Angiodevice International GmbHInventors: Louis C. Sehl, Olof Mikael Trollsas, Donald G. Wallace, David Toman, Frank A. DeLustro, Jacqueline A. Schroeder, George H. Chu
-
Patent number: 8603511Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: GrantFiled: January 18, 2013Date of Patent: December 10, 2013Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
-
Patent number: 8512729Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: GrantFiled: October 31, 2012Date of Patent: August 20, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
-
Patent number: 8377466Abstract: A method of tissue repair is provided using a biocompatible nonimmunogenic adhesive composition. The adhesive composition comprises collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Kits for use in carrying out the method of the invention are also provided, as are pretreated surgically acceptable patches that have been coated with the aforementioned adhesive composition.Type: GrantFiled: October 22, 2004Date of Patent: February 19, 2013Assignee: Angiotech Pharmaceuticals (US), Inc.Inventors: Louis C. Sehl, Olof Mikael Trollsas, Donald G. Wallace, David Toman, Frank A. DeLustro, Jacqueline A. Schroeder, George H. Chu
-
Patent number: 8357378Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: GrantFiled: May 24, 2011Date of Patent: January 22, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
-
Patent number: 8303981Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: GrantFiled: July 1, 2011Date of Patent: November 6, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
-
Publication number: 20120134980Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: July 1, 2011Publication date: May 31, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
-
Publication number: 20110223231Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: May 24, 2011Publication date: September 15, 2011Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
-
Publication number: 20110159075Abstract: Crosslinkable compositions are provided that readily crosslink in situ to provide biocompatible, nonimmunogenic crosslinked materials that may be used as adhesive compositions. The compositions comprise collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Methods for preparing and using the compositions are also provided. Exemplary uses include tissue augmentation, biologically active agent delivery, bioadhesion, prevention of adhesions following surgery or injury, and coating of surgically acceptable patches and solid implants, the latter including sutures.Type: ApplicationFiled: December 27, 2010Publication date: June 30, 2011Applicant: ANGIODEVICE INTERNATIONAL GMBHInventors: Louis C. Sehl, Olof Mikael Trollsas, Donald G. Wallace, David Toman, Frank A. DeLustro, Jacqueline A. Schroeder, George H. Chu
-
Patent number: 7883693Abstract: Crosslinkable compositions are provided that readily crosslink in situ to provide biocompatible, nonimmunogenic crosslinked materials that may be used as adhesive compositions. The compositions comprise collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Methods for preparing and using the compositions are also provided. Exemplary uses include tissue augmentation, biologically active agent delivery, bioadhesion, prevention of adhesions following surgery or injury, and coating of surgically acceptable patches and solid implants, the latter including sutures.Type: GrantFiled: January 31, 2006Date of Patent: February 8, 2011Assignee: AngioDevice International GmbHInventors: Louis C. Sehl, Olof Mikael Trollsas, Donald G. Wallace, David Toman, Frank A. DeLustro, Jacqueline A. Schroeder, George H. Chu
-
Patent number: 7871637Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.Type: GrantFiled: September 21, 2007Date of Patent: January 18, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich, Donald G. Wallace, Narinder S. Shargill, Felix Vega
-
Publication number: 20100233246Abstract: The present invention relates generally to synthetic polymer compositions that form interpenetrating polymer networks. In a preferred embodiment, the compositions comprise two multifunctionally activated synthetic polymers, along with a tensile strength enhancer. Such compositions form matrices that exhibit superior cohesive strength and in many instances can serve as adequate replacements for surgical means of attaching tissues, such as sutures, sponges and medical staples.Type: ApplicationFiled: May 25, 2010Publication date: September 16, 2010Applicant: ANGIOTECH PHARMACEUTICALS (US), INC.Inventors: Louis C. Sehl, Olof Mikael Trollsas, Donald G. Wallace, David Toman, Frank A. DeLustro, Jacqueline A. Schroeder, George H. Chu
-
Patent number: 6833408Abstract: A method of tissue repair is provided using a biocompatible nonimmunogenic adhesive composition. The adhesive composition comprises collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Kits for use in carrying out the method of the invention are also provided, as are pretreated surgically acceptable patches that have been coated with the aforementioned adhesive composition.Type: GrantFiled: September 30, 2002Date of Patent: December 21, 2004Assignee: Cohesion Technologies, Inc.Inventors: Louis C. Sehl, Olof Mikael Trollsas, Donald G. Wallace, David Toman, Frank A. DeLustro, Jacqueline A. Schroeder, George H. Chu
-
Patent number: 6653450Abstract: The invention provides recombinant procollagen chains having a natural collagen chain separated from one or two propeptides by one or two non-natural site-specific proteolytic agent (e.g., protease) recognition sites. A wide variety of propeptides and site-specific proteolytic agent recognition sites may be used: the selection of particular site-specific proteolytic agent/recognition site pairs is based on the conformation of the resulting procollagen, the availability of the site-specific proteolytic agent, the compatibility of the proteolysis with production of mature collagen, among other factors. Recombinant collagens chains are produced by contacting the subject recombinant procollagen chains with the appropriate site-specific proteolytic agents. Nucleic acids encoding the subject procollagen chains operably linked to transcription regulatory elements are used in vectors and cells for the production of recombinant collagen.Type: GrantFiled: July 22, 1994Date of Patent: November 25, 2003Assignee: Cohesion Technologies, Inc.Inventors: Richard A. Berg, Paul David Toman, Donald G. Wallace
-
Patent number: 6624245Abstract: A method is provided for the rapid formation of a biocompatible gel, and may be carried out in situ, i.e., at a selected site within a patient's body. The method involves admixing a biocompatible crosslinking component A having m sulfhydryl groups wherein m≧2 and a biocompatible crosslinking component B having n sulfhydryl-reactive groups wherein n≧2 and m+n>4, wherein the sulfhydryl-reactive groups are capable of covalent reaction with the sulfhydryl groups upon admixture of the components under effective crosslinking conditions to form a gel in less than one minute. Suitable reaction conditions for carrying out the crosslinking reaction will depend on the particular components and the type of reaction involved; that is, the “effective crosslinking conditions” may involve reaction in bulk or in a solvent, addition of a base, and/or irradiation of the admixture in the presence of a free radical initiator.Type: GrantFiled: November 5, 2001Date of Patent: September 23, 2003Assignee: Cohesion Technologies, Inc.Inventors: Donald G. Wallace, Gregory M. Cruise, Woonza M. Rhee, Jacqueline Anne Schroeder, George T. Coker, III, Marcee M. Maroney, Olof Mikael Trollsas
-
Publication number: 20030119985Abstract: A method of tissue repair is provided using a biocompatible nonimmunogenic adhesive composition. The adhesive composition comprises collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Kits for use in carrying out the method of the invention are also provided, as are pretreated surgically acceptable patches that have been coated with the aforementioned adhesive composition.Type: ApplicationFiled: September 30, 2002Publication date: June 26, 2003Inventors: Louis C. Sehl, Olof Mikael Trollsas, Donald G. Wallace, David Toman, Frank A. DeLustro, Jacqueline A. Schroeder, George H. Chu
-
Publication number: 20020193448Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: April 21, 2000Publication date: December 19, 2002Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa